Oruka Therapeutics, Inc.
ORKA
$14.51
-$0.925-5.99%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -15.87% | -14.02% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 13.33% | -33.03% | |||
| Operating Income | -13.33% | 33.03% | |||
| Income Before Tax | -17.02% | 37.11% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -17.02% | 37.11% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -17.02% | 37.11% | |||
| EBIT | -13.33% | 33.03% | |||
| EBITDA | -13.32% | 33.04% | |||
| EPS Basic | -16.11% | 26.99% | |||
| Normalized Basic EPS | -15.88% | 32.05% | |||
| EPS Diluted | -16.11% | 26.99% | |||
| Normalized Diluted EPS | -15.88% | 32.05% | |||
| Average Basic Shares Outstanding | 1.00% | -4.97% | |||
| Average Diluted Shares Outstanding | 1.00% | -4.97% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||